drugset / Trial / NCT02172469

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02172469

Phase 3 Completed 215 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg once daily) and Atrovent® MDI (2 puffs of 20µg q.i.d.) among Filipino patients with COPD

Timeline

Start
2001-05
Primary completion
2002-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ipratropium Small molecule 20 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled